{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:40:25Z","timestamp":1792845625844,"version":"4.5.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Aldosterone, the terminal effector of the renin\u2013angiotensin\u2013aldosterone system, regulates sodium retention, potassium excretion, and blood pressure. Beyond these classical effects, aldosterone-associated and mineralocorticoid receptor (MR)-mediated signaling is implicated in inflammation, oxidative stress, fibrosis, albuminuria, and progressive cardiorenal injury, while its synthesis is regulated by factors beyond angiotensin II. This is particularly relevant in chronic kidney disease (CKD), where persistent renin\u2013angiotensin system (RAS) activation, impaired potassium handling, reduced Klotho, altered aldosterone clearance, and incomplete suppression may sustain aldosterone exposure and MR activation despite conventional RAS blockade. These mechanisms may contribute to residual cardiorenal risk despite standard-of-care therapy. Mineralocorticoid receptor antagonist (MRA) outcome trials establish MR signaling as a therapeutic target in defined CKD populations, but therapeutic benefit from MR blockade should not be interpreted as evidence of biochemical aldosterone excess in all treated patients. This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs). We discuss aldosterone-associated and MR-mediated kidney injury, the cardiorenal axis, albuminuria as a downstream marker of injury and treatment response, and current and emerging therapeutic strategies, including steroidal and nonsteroidal MRAs, ASIs, and combinations with SGLT2 inhibitors. Whereas MRA therapy has established outcome benefits in defined CKD populations, cardiorenal outcome benefit from ASIs remains unestablished; EASi-KIDNEY was discontinued early after independent Data Monitoring Committee review, with detailed results pending.<\/jats:p>","DOI":"10.1093\/ndt\/gfag243","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:50:24Z","timestamp":1792151424000},"source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone and residual cardiorenal risk: pathophysiology and emerging therapeutic strategies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"AlShiab","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermeena","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Abdo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Universidad Aut\u00f3noma de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"Associazione Ipertensione, Nefrologia Trapianto (IPNET), c\/o Nefrologia, Grande Ospedale Metropolitano , Reggio Calabria ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-1996","authenticated-orcid":false,"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[{"name":"Associazione Ipertensione, Nefrologia Trapianto (IPNET), c\/o Nefrologia, Grande Ospedale Metropolitano , Reggio Calabria ,","place":["Italy"]},{"name":"Renal Research Institute , New York, NY ,","place":["USA"]},{"name":"Institute of Molecular Biology and Genetics (Biogem) , Ariano Irpino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"2026102408014767400_bib1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2026102408014767400_bib2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026102408014767400_bib3","doi-asserted-by":"publisher","first-page":"e220249","DOI":"10.1530\/JOE-22-0249","article-title":"Mineralocorticoid receptor signalling in primary aldosteronism","volume":"259","author":"Yang","year":"2023","journal-title":"J Endocrinol"},{"key":"2026102408014767400_bib4","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3390\/biomedicines13092081","article-title":"Aldosterone in chronic kidney disease","volume":"13","author":"Polenus","year":"2025","journal-title":"Biomedicines"},{"key":"2026102408014767400_bib5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026102408014767400_bib6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an International Human Physiology Study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102408014767400_bib7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41574-022-00730-2","article-title":"Primary aldosteronism\u2014a multidimensional syndrome","volume":"18","author":"Turcu","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2026102408014767400_bib8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"2026102408014767400_bib9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamacardio.2026.0068","article-title":"Spectrum of primary aldosteronism and risk of cardiovascular outcomes: the atherosclerosis risk in communities study","volume":"11","author":"Lassen","year":"2026","journal-title":"JAMA Cardiol"},{"key":"2026102408014767400_bib10","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102408014767400_bib11","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2015010093","article-title":"Antiaging gene klotho regulates adrenal CYP11B2 expression and aldosterone synthesis","volume":"27","author":"Zhou","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2026102408014767400_bib12","doi-asserted-by":"publisher","first-page":"ehaf459","DOI":"10.1093\/eurheartj\/ehaf459","article-title":"Mineralocorticoid receptor antagonists and hyperkalaemia: predictable, preventable, manageable, and reversible","author":"Marques","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102408014767400_bib13","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/S0140-6736(26)01009-3","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)","volume":"407","author":"Neuen","year":"2026","journal-title":"Lancet"},{"key":"2026102408014767400_bib14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2604625","article-title":"Finerenone in persons with chronic kidney disease without diabetes","volume":"395","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib16","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102408014767400_bib17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"2026102408014767400_bib18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026102408014767400_bib19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026102408014767400_bib20","doi-asserted-by":"publisher","first-page":"19619","DOI":"10.1073\/pnas.1908706116","article-title":"The single-cell transcriptomic landscape of early human diabetic nephropathy","volume":"116","author":"Wilson","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026102408014767400_bib21","volume-title":"Kidney Interactive Transcriptomics (KIT)","author":"Humphreys Laboratory","year":"2026"},{"key":"2026102408014767400_bib22","first-page":"1029","article-title":"The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications","volume":"39","author":"Seccia","year":"2018","journal-title":"Endocr Rev"},{"key":"2026102408014767400_bib23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1152\/advan.00121.2016","article-title":"Physiology and pathophysiology of potassium homeostasis","volume":"40","author":"Palmer","year":"2016","journal-title":"Adv Physiol Educ"},{"key":"2026102408014767400_bib24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1152\/physrev.00011.2014","article-title":"Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited","volume":"95","author":"Rossier","year":"2015","journal-title":"Physiol Rev"},{"key":"2026102408014767400_bib25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102408014767400_bib26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4049\/jimmunol.167.1.30","article-title":"11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages","volume":"167","author":"Thieringer","year":"2001","journal-title":"J Immunol"},{"key":"2026102408014767400_bib27","doi-asserted-by":"publisher","first-page":"e00995","DOI":"10.1002\/prp2.995","article-title":"Correlation of functional and radioligand binding characteristics of GPER ligands confirming aldosterone as a GPER agonist","volume":"10","author":"Ding","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"2026102408014767400_bib28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ajh\/hpaf183","article-title":"Risk of hypertension and chronic kidney disease following aldosterone dysregulation","volume":"39","author":"Townsend","year":"2026","journal-title":"Am J Hypertens"},{"key":"2026102408014767400_bib29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102408014767400_bib30","doi-asserted-by":"publisher","first-page":"1686480","DOI":"10.3389\/fendo.2025.1686480","article-title":"Data-driven cluster analysis and external validation identify phenotypic subgroups in renin-independent aldosteronism with differential cardiovascular risk and therapeutic implications","volume":"16","author":"Liu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026102408014767400_bib31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2026102408014767400_bib32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/01.CIR.52.1.146","article-title":"Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a \u201cno-salt\u201d culture","volume":"52","author":"Oliver","year":"1975","journal-title":"Circulation"},{"key":"2026102408014767400_bib33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-023-03566-6","article-title":"Extra-adrenal aldosterone: a mini review focusing on the physiology and pathophysiology of intrarenal aldosterone","volume":"83","author":"Xu","year":"2024","journal-title":"Endocrine"},{"key":"2026102408014767400_bib34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.mce.2011.06.026","article-title":"Non-adrenal synthesis of aldosterone: a reality check","volume":"350","author":"MacKenzie","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026102408014767400_bib35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"2026102408014767400_bib36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000480652","article-title":"The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature","volume":"46","author":"Belden","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026102408014767400_bib37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0895-7061(95)00349-5","article-title":"Chymase-dependent angiotensin II forming systems in humans","volume":"9","author":"Urata","year":"1996","journal-title":"Am J Hypertens"},{"key":"2026102408014767400_bib38","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026102408014767400_bib39","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2026102408014767400_bib40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"2026102408014767400_bib41","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"2026102408014767400_bib42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"key":"2026102408014767400_bib43","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet"},{"key":"2026102408014767400_bib44","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib45","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102408014767400_bib47","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in type 1 diabetes and chronic kidney disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib48","article-title":"U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes","author":"Bayer","year":"2026"},{"key":"2026102408014767400_bib49","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jama.2026.9923","article-title":"Finerenone in patients with chronic kidney disease due to glomerular diseases: a randomized clinical trial","volume":"336","author":"Neuen","year":"2026","journal-title":"JAMA"},{"key":"2026102408014767400_bib50","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib51","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s40262-023-01312-9","article-title":"The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone","volume":"62","author":"Heinig","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026102408014767400_bib52","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12933-025-03014-x","article-title":"Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)","volume":"24","author":"Tanaka","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026102408014767400_bib53","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","article-title":"Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial","volume":"406","author":"Heerspink","year":"2025","journal-title":"Lancet"},{"key":"2026102408014767400_bib54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"key":"2026102408014767400_bib55","author":"AstraZeneca Pharmaceuticals LP","year":"2026"},{"key":"2026102408014767400_bib56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"2026102408014767400_bib57","article-title":"Boehringer provides update on EASi-KIDNEY trial","author":"Boehringer Ingelheim","year":"2026"},{"key":"2026102408014767400_bib58","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102408014767400_bib59","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2026102408014767400_bib60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41581-025-01008-2","article-title":"Urine as a source of biomarkers and biological knowledge in chronic kidney disease","volume":"22","author":"Vlahou","year":"2026","journal-title":"Nat Rev Nephrol"},{"key":"2026102408014767400_bib61","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026102408014767400_bib62","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102408014767400_bib63","doi-asserted-by":"publisher","first-page":"ehag098","DOI":"10.1093\/eurheartj\/ehag098","article-title":"2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA)","author":"Damman","year":"2026","journal-title":"Eur Heart J"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag243\/72045293\/gfag243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag243\/72045293\/gfag243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:01:56Z","timestamp":1792843316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag243\/8931556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag243","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"article-number":"gfag243"}}